Cleveland BioLabs sets up Russian joint venture
This article was originally published in Scrip
Executive Summary
Cleveland BioLabs of the US has set up a 50/50 joint venture with Bioprocess Capital Ventures, a Russian venture capital fund, to develop Curaxin compounds for cancer applications.